The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from
potentially harmful endogenous and exogenous substances. BBB active drug efflux …

Resistance to drug treatment is an important hurdle in the therapy of many brain disorders,
including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with …

In this review we give an overview of the physiological functions of a group of ATP binding
cassette (ABC) transporter proteins, which were discovered, and still referred to, as …

The blood–brain barrier (BBB) serves as a protective mechanism for the brain by preventing
entry of potentially harmful substances from free access to the central nervous system …

Drug‐resistant epilepsy with uncontrolled severe seizures despite state‐of‐the‐art medical
treatment continues to be a major clinical problem for up to one in three patients with …

Medical intractability, ie the absence of any response to anti-epileptic drug (AED) therapy, is
an unresolved problem in many patients with epilepsy. Mechanisms of intractability are not …

Purpose: Overexpression of multidrug transporters such as P‐glycoprotein (P‐gp) may play
a significant role in pharmacoresistance, by preventing antiepileptic drugs (AEDs) from …

Purpose: P‐glycoprotein (P‐gp) has been implicated in the causation of refractory epilepsy.
The expression and efflux efficiency of P‐gp is influenced by a polymorphism (C3435T) in …

Epileptic seizures drive expression of the blood–brain barrier efflux transporter P-
glycoprotein via a glutamate/cyclooxygenase-2 mediated signalling pathway. Targeting this …

Temporal lobe epilepsy (TLE) is the most common form of focal epilepsies in adults. It is
often initiated by an insult or brain injury which triggers a series of alterations which …